Alvotech (ALVO) |
|
11.8 -0.16 (-1.34%)
|
01-27 14:12 |
|
Open: |
11.8001 |
Pre. Close: |
11.96 |
|
High:
|
11.99 |
Low:
|
11.76 |
|
Volume:
|
34,536 |
Market Cap:
|
2,934(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:26 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 15.18 One year: 17.73 |
| Support: |
Support1: 9.84  Support2: 7.9 |
| Resistance: |
Resistance1: 13 Resistance2: 15.18 |
| Pivot: |
11.96 |
| Moving Average: |
MA(5): 11.91 MA(20): 11.47
MA(100): 7.9 MA(250): 0 |
| MACD: |
MACD(12,26): 0.8  Signal(9): 0.9 |
| Stochastic oscillator: |
%K(14,3): 61.2 %D(3): 64.1 |
| RSI: |
RSI(14): 64.9 |
| 52-week: |
High: 13 Low: 5.19 |
| Average Vol(K): |
3-Month: 104 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALVO ] has closed above bottom band by 39.9%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12 - 12.08 |
12.08 - 12.13 |
|
Low:
|
11.55 - 11.65 |
11.65 - 11.71 |
|
Close:
|
11.68 - 11.81 |
11.81 - 11.91 |
|
Company Description |
|
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland. |
Headline News |
Sun, 29 Jan 2023
Dawgs lose to Pensacola for 2nd straight night - Roanoke Times
Sun, 29 Jan 2023
AbbVie's global bestseller Humira to face knockoffs this week (NYSE ... - Seeking Alpha
Tue, 24 Jan 2023
Health Care Sector Update for 01/24/2023: DHR, JNJ, ALVO, IBB, XLV - Nasdaq
Tue, 24 Jan 2023
Despite shrinking by US$115m in the past week, Alvotech (NASDAQ:ALVO) shareholders are still up 21% over 1 year - Yahoo Finance
Tue, 24 Jan 2023
Alvotech (ALVO) and Bioventure Announce Approval of AVT02 as ... - StreetInsider.com
Fri, 20 Jan 2023
Patient Positioning Devices Market Is Booming Worldwide 2023 ... - Digital Journal
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
0 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
7.214e+007 (%) |
|
% Held by Institutions
|
73.6 (%) |
|
Shares Short
|
150 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.5215e+008 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
-15.5 |
|
Operating Margin (%)
|
-208 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
1 |
|
Gross Profit (p.s.)
|
717.07 |
|
Sales Per Share
|
2.34463e+008 |
|
EBITDA (p.s.)
|
9.67805e+007 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-285 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
201030 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
